Data 'reassuring' on topical calcineurin inhibitors and skin cancer risk
First post-marketing surveillance study in patients with atopic dermatitis finds no association
Treating atopic dermatitis with the topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus does not appear to increase the risk of keratinocyte carcinoma, according to an industry-funded study.
In the US, TCIs carry a black-box warning about the potential for increased skin cancer risk, Dr Maryam Asgari of Massachusetts General Hospital, in Boston, and colleagues note in JAMA Dermatology.
The researchers examined health-plan data from 2002-13 and identified more than 93,000 patients